At a glance

5-Amino-1MQ Quick Reference

Oral research dose: 50–150mg daily
Morning only
SubQ research dose: 1–5mg daily
5 days on, 2 days off—or daily
Cycle length: 6–8 weeks
Oral use, followed by time off and reassessment
Research target: NNMT inhibition
Energy expenditure rather than appetite suppression

Overview

What Is 5-Amino-1MQ?

5-Amino-1MQ is a small molecule compound that blocks an enzyme called NNMT (nicotinamide N-methyltransferase). Unlike most compounds in this library, it is not a peptide. Its small-molecule structure allows it to survive the digestive system intact and be taken orally.

The compound was developed by researchers studying new approaches to obesity and metabolic dysfunction. In animal studies, mice treated with 5-Amino-1MQ lost body fat without a reduction in food intake. The observed effect was associated with increased cellular energy expenditure rather than appetite suppression.

Mechanism

5-Amino-1MQ Mechanism of Action

Targeting NNMT

NNMT is an enzyme found in fat and muscle tissue. High levels of NNMT slow down your metabolism and encourage your body to store fat. By inhibiting this enzyme, 5-Amino-1MQ stops that slowdown.

Preserving NAD+

Blocking NNMT saves a vital molecule called NAD+ (nicotinamide adenine dinucleotide) from being depleted. NAD+ is the core fuel your cells use to create energy.

Boosting Energy and Mitochondria

With higher NAD+ levels, your mitochondria (the power plants inside your cells) work better. Your body burns stored fat for fuel more efficiently instead of holding onto it.

Activating Longevity Genes

More circulating NAD+ helps activate proteins like SIRT1, often called a longevity gene, which supports cellular repair and healthy aging.

Research findings

5-Amino-1MQ Benefits

Research interest centers on body composition, cellular energy use, glucose regulation, and tissue metabolism. These potential benefits have been reported in animal or laboratory models and have not been established in published human clinical trials.

Current evidence level: preclinical

Fat Loss Without Appetite Suppression

Animal data showed reduced white adipose tissue and smaller fat cells without reduced food intake.

Preserved Muscle Mass

NNMT inhibition may help preserve lean tissue while reducing fat through NAD+ and SIRT1-related pathways.

Improved Insulin Sensitivity

Animal studies reported improvements in glucose tolerance and insulin sensitivity following NNMT inhibition.

Improved Liver Pathology

Preclinical findings included improvements in fatty-liver markers and obesity-associated liver pathology.

Muscle Regeneration Support

Animal research found activation of aged muscle stem cells and improved regenerative capacity.

Microbiome Changes

When combined with dietary improvement, 5-Amino-1MQ shifted the gut microbiome in favorable directions in preclinical research.

Protocol planning

5-Amino-1MQ Dosing Protocol

5-Amino-1MQ is discussed in both oral and subcutaneous research protocols, but the dose ranges and cycling patterns are not interchangeable. Published human trials have not established a validated dose or treatment schedule.

Research dose50–150mg daily

Starting point: 50mg daily, increasing only as needed.
Timing: Morning is more common. Evening use may be more likely to disrupt sleep.
Cycle: 6–8 weeks, followed by roughly equal time off and reassessment.
With food?: No human study has compared the two. Food may be easier on the stomach but could change absorption.

Route matters. Oral and subcutaneous protocols use very different dose ranges. Do not convert an oral milligram dose directly into an injectable dose.

Preparation

5-Amino-1MQ Reconstitution

Example concentration

10mg vial + 2mL bacteriostatic water

Result5mg/mL

Reconstitution steps

1

Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2

Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume down the inside wall of the vial.

3

Dissolve gently

Swirl or roll the vial until the contents are dissolved.

4

Label the vial

Record the reconstitution date and final concentration before storing it.

N=1 reports

5-Amino-1MQ Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Modest fat loss. Oral users often describe gradual changes over 6–8 weeks, frequently around 3–6 pounds when diet and training remain consistent.
Appetite generally unchanged. This aligns with the proposed energy-expenditure mechanism rather than appetite suppression.
Mild warmth or energy. Some users notice subtle thermogenesis or increased baseline energy within the first week.
Lower SubQ doses dominate. Community use centers on 1–2mg daily, with 1mg often described as sufficient.

Negative & Mixed Reports

Some users notice very little. Reports are less favorable when nutrition, training, and sleep are inconsistent.
The effect is often subtle. Users with an established routine are more likely to distinguish a modest change from normal fluctuations.
More is not necessarily better. Injectable doses of 5–10mg are commonly described as excessive without a clear practical advantage.
Route changes the experience. Oral and SubQ reports should not be treated as interchangeable because their dose ranges and cycling patterns differ substantially.

Stacking & synergy

5-Amino-1MQ Stacking & Synergy

These combinations are mechanistic or community-discussed pairings rather than validated 5-Amino-1MQ combination protocols. Introduce compounds separately and track attribution carefully.

5-Amino-1MQ + SS-31 + NAD+

SS-31 supports mitochondrial membrane integrity, NAD+ provides metabolic fuel, and 5-Amino-1MQ helps block the NNMT pathway that can drain nicotinamide.

5-Amino-1MQ + MOTS-c + NAD+

MOTS-c supports metabolic optimization, NAD+ powers cellular energy pathways, and 5-Amino-1MQ helps preserve the NAD+ pool.

5-Amino-1MQ + GLP-1 Agonists

Retatrutide, semaglutide, and tirzepatide work primarily through appetite control, while 5-Amino-1MQ targets energy expenditure.

Safety notes

5-Amino-1MQ Side Effects & Safety

Animal studies reported no observable adverse effects at the doses tested. No acute toxicity or adverse events were documented across the published preclinical studies. However, no human safety data currently exists.

Because 5-Amino-1MQ has no published human clinical trial data, user-reported side effects should be interpreted cautiously and not treated as a complete safety profile.

Common User Reports

Mild jitteriness or increased energy, usually during the first few days.
Subtle increase in body warmth or thermogenesis.
Injection-site redness, irritation, or local discomfort with injectable use.
Sleep disruption when taken too late in the day.

Less Common Reports

Headache.
Occasional nausea.
Feeling overstimulated in sensitive users.
Difficulty sleeping when dosed too late.

Most user-reported side effects appear dose-dependent and often resolve within the first week.

5-Amino-1MQ Precautions

Avoid or Discuss With a Clinician If

Active cancer or history of cancer, because NNMT has complex roles in cancer biology and its inhibition may vary depending on tumor type.
Pregnancy or breastfeeding, because it has not been studied and risks are unknown.
Severe liver or kidney disease, because metabolism and clearance may be affected.

Use caution with

History of anxiety or stimulant sensitivity.
Medications or supplements that affect NAD+ or methyl donor pathways.
Other compounds that increase metabolic rate.

Regulatory status: 5-Amino-1MQ is not FDA approved for human use, and no published human clinical trials have established its safety or efficacy.

Final verdict

Peptide Protocols Verdict on 5-Amino-1MQ

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Our opinionated opinion

We actually like this molecule—even though it isn’t technically a peptide and merely travels in peptide circles. But we think it makes the most sense for people dealing with obesity or stubborn metabolic dysfunction, where the NNMT mechanism is at least directionally relevant. If you’re already lean and metabolically healthy, we don’t see a compelling reason to reach for it.

The practical advantage is the oral option. For researchers tired of injections—or anyone who wants something that works through energy metabolism rather than appetite suppression—that makes 5-Amino-1MQ especially interesting.

Our reservation is simple: the human data still aren’t there. Interesting target, promising preclinical evidence and convenient administration—but far more certainty online than the published evidence currently supports.